# US 2019/0314519 A1 · Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314519 A1
- Document ID: US20190314519A1
- Status: Published application
- Kind: A1
- Application number: 16/343,140
- Filed: 2017-10-18
- Published: 2019-10-17
- Earliest claimed: 2016-10-18
- Assignees: Seattle Genetics, Inc.
- Applicants: Seattle Genetics, Inc.
- Inventors: Christopher Scott Neumann; Kathleen Olivas
- Web page: https://patentgrep.com/patent/US20190314519A1

## CPC

- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 47/51: the non-active ingredient being a modifying agent
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 5/0202: {containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.

## Claims

### Claim 1

A Ligand Drug Conjugate (LDC) composition, wherein the composition is represented by the structure of:
or a pharmaceutically acceptable salt thereof, wherein
L is a Ligand Unit;
D is a NAMPT Drug Unit represented by the general structure of:
or a pharmaceutically acceptable salt thereof, wherein
the wavy line indicates the site of covalent attachment to LO or LR, depending on the presence or absence of LO;
HN is a NAMPT Head Unit, wherein the NAMPT Head Unit is a C5-C24 heteroaryl or partially aromatic C9-C24 heterocyclyl, optionally substituted, wherein the C5-C24 heteroaryl or partially aromatic C9-C24 heterocyclyl is comprised of an optionally substituted 5- or 6-membered nitrogen-containing heteroaromatic ring system corresponding to the heterocycle of nicotinamide, and is capable of interacting with enzymatically competent NAMPT homodimer at its nicotinamide mononucleotide binding site when the NAMPT Drug Unit is released from a Ligand Drug Conjugate compound of the composition as a NAMPT inhibitor (NAMPTi) compound or derivative thereof;
DA is a Donor-Acceptor Unit wherein the Donor-Acceptor Unit is or is comprised of a hydrogen bond donor acceptor functional group and is bonded to a carbon skeletal atom at position 2 or 3 of the 5-membered nitrogen-containing heteroaromatic ring system or at position 3 or 4 of the 6-membered nitrogen-containing heteroaromatic ring system, with optional formal cyclization of DA back to an adjacent skeletal carbon atom of the 6-membered nitrogen-containing heteroaromatic ring system through an introduced optionally substituted non-aromatic carbon atom or an optionally substituted nitrogen, oxygen or sulfur atom resulting in a partially aromatic or fully aromatic fused 6,5- or 6,6-ring system,
wherein said bonding of DA is in relation to a skeletal nitrogen atom of the 5- or 6 membered nitrogen-containing heteroaromatic ring system and wherein said formal cyclization to the adjacent carbon atom of the 6-membered nitrogen-containing heteroaromatic ring system substantially retains the hydrogen bonding capability of the donor acceptor functional group of DA in absence of said cyclization;
IN is an Interconnecting Unit, wherein the Interconnecting Unit is or is comprised of —X1—[C(═O)]0,1—, —X1—S(═O)1,2-, —X2—C6-C24 arylene-[C(═O)]0,1—, —X2—C6-C24 arylene-[S(═O)1,2]0,1, —X2—C6-C24 arylene-O—, —X2—C5-C24 heteroarylene-[C(═O)0,1]—, —X2—C5-C24 heteroarylene-[S(═O)1,2]0,1, —X2—C5-C24 heteroarylene-O— or —X2—C3-C20 heterocyclo-[C(═O)0,1]—, wherein the arylene, heteroarylene and heterocyclo are optionally substituted;
X1 is optionally substituted C5-C7 alkylene;
X2 is absent or is an optionally substituted C1-C4 alkylene;
TN is a NAMPT Tail Unit, wherein the NAMPT Tail Unit is or is comprised of an optionally substituted amino-alcohol residue or a carboxylic acid-alcohol residue, the —O— or optionally substituted nitrogen of which is the site of covalent attachment to LO, or LR, depending on the presence or absence of LO, or
TN is or is comprised of an optionally substituted benzamide moiety, the amide nitrogen atom of which is bonded to IN with optional cyclization of that atom back to IN or to the remainder of TN, and the aromatic ring of which is at least substituted with a hydroxyl, thiol or amino residue, the —O—, —S— or optionally substituted nitrogen atom of which at position 3 or 4 relative to the site at which the amide carbonyl carbon atom is attached is the site of covalent attachment to LO or LR, depending on the presence or absence of LO, or
TN is or is comprised of an optionally substituted aryl or biaryl moiety, an aromatic skeletal atom of which is bonded to IN, or to the remainder of TN, and wherein an aromatic ring of which is at least substituted with a hydroxyl, thiol or an amino residue, the —O—, —S— or optionally substituted nitrogen of which is the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively; and
wherein TN or the remainder thereof is bonded to IN, wherein said remainder is an optionally substituted C2-C7 heteroalkylene or an optionally substituted C5-C6 heterocyclo,
LR is a primary linker, which interconnects the Ligand Unit and Drug Unit optionally through LO, as indicated, which is an optional secondary linker;
subscripts a and b independently are 0 or 1, indicating the absence or presence, respectively, of A or B;
subscript n is 1, 2, 3 or 4;
A is an first optional Stretcher; and
B is a Branching Unit, when subscript b is 1 and subscript n is 2, 3 or 4, or B is absent, so that subscript b is 0, when subscript n is 1,
wherein each of A and B is an independently selected single unit or is optionally comprised or consists of at least two, three or four independently selected subunits;
Y is a Spacer Unit; and subscript y is 0, 1 or 2, indicating the absence or presence of one or two of Y, respectively,
provided that when subscript y is 1, Y is a Spacer Unit covalently attached to a heteroatom or moiety thereof of TN selected from the group consisting of —O—, —S— and optionally substituted nitrogen,
provided that when subscript y is 2 so that Yy is —Y—Y, Y is a first Spacer Unit and Y′ is a second Spacer Unit or a functional group comprised of the optionally substituted heteroatom from TN; and
provided that subscript y is 1 or 2 when W is a Glucuronide Unit of formula Y(W′), in which instance subscript y is inclusive of a first Spacer Unit Y, wherein that Spacer Unit is a required self-immolative Spacer Unit; and
subscript w is 0 or 1, indicating the absence or presence, respectively, of W; wherein
when subscript w is 1, W is a Peptide Cleavable Unit or said Glucuronide Unit in which W′ represents a carbohydrate moiety with glycosidic bonding to the required self-immolative Spacer Unit through an optionally substituted heteroatom, wherein enzymatic or non-enzymatic cleavage of either Unit initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from a drug linker moiety of a compound comprising the Ligand Drug Conjugate composition; and
when subscript w is 0, which indicates the absence of a Cleavable Unit, enzymatic or non-enzymatic cleavage of the bond between LR and LO, when LO is present, or the bond between LR and D, when LO is absent, initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof;
subscript p is an average drug linker moiety loading when subscript n is other than 1 or an average drug loading when subscript n is 1, wherein subscript p in either instance is a number ranging from about 1 to about 24; and
wherein a compound comprising the Ligand Drug Conjugate composition corresponds in structure to that of Formula 1 or Formula 2 in which p is replaced by p′, wherein p′ is an integer ranging from 1 to 24.

### Claim 2 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein the NAMPT Head (HN) Unit is a pyridine mimetic.

### Claim 3 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein the Donor Acceptor (DA) Unit is comprised of an optionally substituted amide functional group or bioisostere thereof.

### Claim 4 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein HN-DA is a nicotinamide mimetic.

### Claim 5 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein the 6-membered nitrogen-containing heteroaromatic ring system of HN is that of pyridine with optional cyclization of DA back to the pyridine aromatic ring system through an introduced aromatic oxygen, sulfur or an optionally substituted nitrogen atom so that HN contains a 6-5 fused aromatic ring system.

### Claim 6 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein each of the NAMPT homodimers of the enzymatically competent NAMPT homodimer has the amino acid sequence of SEQ ID 1.

### Claim 7 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein the NAMPT Head Unit has the structure of:
or a pharmaceutically acceptable salt thereof,
in particular, having the structure of:
or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, —NH2 or chloro;
R2 is fluoro;
R3 is hydrogen or —NH2; and
the wavy line indicates the site of covalent attachment to DA and an adjacent aromatic carbon atom thereto is the site of said optional cyclization by DA to HN.

### Claim 8 (depends on 3)

The Ligand Drug Conjugate composition of claim 3, wherein the Donor-Acceptor Unit has the structure of:
in particular, having the structure of:
wherein R4 is hydrogen or optionally substituted C1-C4 alkyl;
DA is optionally cyclized to HN, wherein said cyclization is to the sp2 carbon atom proximal to the carbonyl carbon (as indicated) through an introduced optionally substituted non-aromatic carbon atom or an optionally substituted aromatic heteroatom;
the wavy line indicates the site of covalent attachment to HN, and the aromatic carbon atom adjacent thereto is the site of said optional cyclization by DA to HN; and
the pound sign (#) indicates the site of covalent attachment to IN, or
wherein the Donor-Acceptor Unit has the structure of:
or a pharmaceutically acceptable salt thereof,
in particular, having the structure of:
or a pharmaceutically acceptable salt thereof, wherein
XD is O, S or NRD, wherein the nitrogen atom is optionally protonated and RD is hydrogen or optionally substituted C1-C4 alkyl;
each R4 is independently selected from the group consisting of hydrogen and optionally substituted C1-C4 alkyl, or both R4 together with the nitrogen atoms to which they are attached and the intervening carbon atom(s) define an optionally substituted C5-C6 heterocyclo;
the pound sign (#) indicates the site of covalent attachment to IN; and the wavy line indicates the site of covalent attachment to HN,
wherein DA is optionally cyclized back to an adjacent aromatic carbon atom of HN, wherein said cyclization is from the indicated nitrogen atom so that R4 bonded thereto is replaced by a covalent bond to said adjacent aromatic carbon atom, or is from XD when XD is —NRD, either directly or through an introduced —S(═O)0-2 moeity, in which either instance RD is replaced by a bond to said adjacent carbon atom or the sulfur atom of said introduced moiety.

### Claim 9 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein HN-DA- has the structure of:
or a pharmaceutically acceptable salt thereof, wherein
R4 is hydrogen or optionally substituted C1-C4 alkyl; and
the wavy line indicates the site of covalent attachment to IN, and
wherein the sp2 carbon atom proximal to the carbonyl carbon atom is the site (as indicated) of optional cyclization to HN through an introduced optionally substituted non-aromatic carbon atom or an optionally substituted aromatic heteroatom.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The Ligand Drug Conjugate composition of any one of claims 1 to 9, wherein the NAMPT Tail Unit is or is comprised of an optionally substituted amino alcohol moeity,
wherein the oxygen atom of the alcohol is the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively,
in particular having the structure of.
or a pharmaceutically acceptable salt thereof, wherein
R4 is hydrogen or optionally substituted C1-C4 alkyl;
the wavy line indicates the site of covalent attachment to IN; and
the pound sign (#) indicates the site of covalent to LO or LR, depending on the presence or absence of LO, respectively, or
wherein the Tail Unit is or is comprised of an optionally substituted benzamide moeity having a functional group providing a heteroatom that is the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively,
in particular, having the structure of:
wherein Xb is —S— —O— or —NH—, optionally substituted; and
R4 is hydrogen or optionally substituted C1-C4 alkyl, wherein
the benzamide moeity is optionally cyclized to IN, wherein the amide nitrogen atom of the benzamide moiety is the site of said cyclization so that R4 is replaced by a covalent bond to IN,
more particularly, having the structure of:
wherein the wavy line indicates the site of covalent attachment to IN;
the pound sign (#) indicates the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively.

### Claim 11 (depends on 10)

The Ligand Drug Conjugate composition of claim 10, wherein IN is —CH2—(CH2)3-7—CH2—, —CH2—(CH2)3-7—CH2—O—, —CH2—(CH2)3-7—C(═O)—, —CH2—(CH2)3-7—S(═O)2— or —CH2—(CH2)3-7—S(═O)—.

### Claim 12 (depends on 11)

The Ligand Drug Conjugate composition of claim 11, wherein —IN-TN- has the structure of:
wherein Xb is —NH—, —O— or —S—;
the wavy line indicates the site of covalent attachment to DA; and
the pound sign (#) indicates the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively.

### Claim 13 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein the NAMPT Drug Unit has the structure of:
or a pharmaceutically acceptable salt thereof, wherein
the pound sign (#) indicates the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively.

### Claim 14 (depends on 1, 13)

The Ligand Drug Conjugate composition of claim 1 or 13, wherein L-LR- has the structure of:
or a pharmaceutically acceptable salt thereof, wherein
the indicated (#) nitrogen, carbon or sulfur atom is from the Ligand Unit; and wherein the wavy line indicates the site of covalent attachment to the remainder of the Conjugate structure.

### Claim 15 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein the composition is represented by the structure(s) of Formula 1 and/or Formula 2:
or a pharmaceutically acceptable salt thereof, wherein
S is a sulfur atom of the Ligand Unit, which in Formula 2 is bonded to the carbon atom α or β to the carboxylic acid functional group of the indicated succinic acid amide (M3) moiety;
R6 is hydrogen or an optionally substituted C1-C6 alkyl, which in Formula 2 is bonded to the saturated carbon atom adjacent to the carbon substituted by L-S—;
AO is a second optional Stretcher Unit;
BU is a Basic Unit and Ra2 is an optionally substituted C1-C12 alkyl group; and
the dotted curved line indicates optional cyclization so that in the absence of said cyclization BU is an acyclic Basic Unit or in the presence of said cyclization BU is a cyclized Basic Unit in which Ra2 and BU together with the carbon atom to which both are attached, define an optionally substituted spiro C3-C20 heterocyclo containing a skeletal basic nitrogen atom of a secondary or tertiary amine functional group as the basic function group of the cyclic Basic Unit,
wherein the basic nitrogen atom of the acyclic Basic Unit or cyclic Basic Unit is optionally suitably protected by a nitrogen protecting group, dependent on the degree of substitution of the basic nitrogen atom, or is optionally protonated,
in particular, having the structure of:
wherein [HE] as AO is an optional Hydrolysis Enhancing Unit;
subscript w is 1;
W is Peptide Cleavable Unit; and
wherein the remaining variable groups retain their previous meanings, wherein protease action on the Peptide Cleavable Unit results in cleavage of the W-J′ bond within a drug linker moiety of a compound comprising the Ligand Drug Conjugate composition to initiate release of the NAMPT Drug Unit as NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound, or
W is a Glucuronide Unit of formula —Y(W′)— having the structure of:
wherein Su is a carbohydrate moiety and -E′- represents an optionally substituted heteroatom of an glycosidic bond cleavable by a glycosidase so that Su-E′ is W′ and the remainder of the Glucuronide Unit structure is a self-immolative Spacer Unit bonded to W′;
J′ is an independently selected heteroatom, optionally substituted, and the wavy line thereto is the site of covalent attachment resistant to enzymatic or non-enzymatic cleavage under normal physiological conditions wherein said site of covalent attachment is to A when subscript a is 1 or to the indicated LSS primary linker when subscript a is 0; and
V, Z1, Z2 and Z3 are independently ═N— or ═C(R24)—, wherein each R24 is independently selected from the group consisting of hydrogen and C1-C12 alkyl, C2-C12 alkenyl and C2-C12 alkynyl, optionally substituted, and halogen, an electron withdrawing group, an electron donating group, -E′-Su, and —C(R8)(R9)—,
provided that one and only one —C(R8)(R9)— moiety and one and only one -E′-Su moiety is present,
wherein one of V, Z1, Z2 and Z3 is ═C(R24)— in which R24 is —C(R8)(R9)— and another of V, Z1, Z2 and Z3 is ═C(R24)— in which R24 is -E′-Su,
provided the —C(R8)(R9)— and -E′-Su moieties are ortho or para to each other;
R8 and R9 independently are hydrogen, or C1-C12 alkyl, C2-C12 alkenyl or C2-C12 alkynyl, optionally substituted, or C6-C20 aryl or C5-C20 heteroaryl, optionally substituted,
or
R8 and R9 together with the carbon atom to which both are attached define an optionally substituted C5-C20 carbocyclo; and
R′ is hydrogen or —NO2, or other electron withdrawing group or —OC1-C6 alkyl, or other electron donating group; and
wherein the wavy line adjacent to the —C(R8)(R9)— moiety indicates the site of covalent attachment of the Glucuronide Unit to Y′ when subscript y is 2, or to D when subscript y is 1, and
wherein the remaining variable groups of the composition structure(s) are as previously defined for W as a Peptide Cleavable Unit.

### Claim 16 (depends on 15)

The Ligand-Drug Conjugate composition of claim 15, wherein W is a Glucuronide Unit for which —W—Yy-D has the structure of:
or a pharmaceutically acceptable salt thereof, wherein
Xa is a nitrogen atom from a primary or secondary amine functional group of TN;
Xb is an oxygen atom from an alcohol functional group or a sulfur atom from a thiol functional group of TN,
or —W—Yy-D has the structure of:
or a pharmaceutical acceptable salt thereof,
R51, R52 and R53 independently are hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C6-C14 aryl, or optionally substituted C-linked C3-C8 heteroaryl,
or R51 and R52 together with the nitrogen and carbon atoms to which both are attached define an azetidine, pyrrolidine, piperidine or homopiperidine heterocyclo, and R53 is hydrogen;
and in either —W—Yy-D structure:
R45 is —CH2OH or —CO2H;
R′ is hydrogen or —NO2 or other electron withdrawing group;
J′ is an optionally substituted heteroatom, and the wavy line thereto is the site of covalent attachment resistant to enzymatic or non-enzymatic cleavage under normal physiological conditions; and
wherein O* represents the oxygen atom from an alcohol functional group of TN and O′ represents the oxygen atom of an O-glycosidic bond cleavable by a glycosidase, wherein said cleavage within a drug linker moiety of a compound comprising the Ligand Drug Conjugate composition initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative from that Ligand Drug Conjugate compound,
or, wherein
W is a Peptide Cleavable Unit for which —Yy-D- has the structure of:
or a pharmaceutical acceptable salt thereof, wherein
Xa is an oxygen atom from an alcohol functional group or a sulfur atom of a thiol functional group of TN;
Xb is a nitrogen atom from a primary or secondary amine functional group of TN, or has the structure of:
or a pharmaceutical acceptable salt thereof, wherein
R′ is hydrogen or —OC1-C6 alkyl or other electron donating group;
R7, R10 and R11 independently are hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C6-C14 aryl, or optionally substituted C-linked C3-C8 heteroaryl,
or R7 and R10 together with the nitrogen and carbon atoms to which both are attached define an azetidine, pyrrolidine, piperidine or homopiperidine heterocyclo, and R11 is hydrogen;
J′ is an optionally substituted heteroatom bonded to W as indicated by the wavy line, wherein cleavage of that bond within a drug linker moiety of a compound comprising the Ligand Drug Conjugate composition initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound; and
the remaining variable groups are as previously defined for W as a Glucuronide Unit.

### Claim 17 (depends on 15)

The Ligand Drug Conjugate composition of claim 15, wherein W is a Glucuronide Unit for which the composition is represented by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
subscript P is 1, 2 or 3; and
subscript Q ranges from 1 to 6,
or by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
Ra2 is hydrogen or C1-C6 alkyl;
BU is an acyclic Basic Unit having the structure of —[C(Ra1)(Ra1)]—[C(Ra1)(Ra1)]0-3—N(Ra3)(Ra3), wherein each Ra1 independently is hydrogen or C1-C4 alkyl, C6-C10 aryl, C5-C10 heteroaryl, (C6-C10 aryl)-C1-C4 alkyl-, or (C5-C10 heteroaryl)-C1-C4 alkyl-, optionally substituted, or two Ra1 together with the carbon(s) to which they are attached and any intervening carbons define an optionally substituted C3-C6 cycloalkyl; and
Ra3 independently are hydrogen, optionally substituted C1-C6 alkyl or Ra3 together with the nitrogen atom to which both are attached define a C3-C6 heterocyclyl in which the basic nitrogen atom is a skeletal atom,
or one of Ra3 is —H and the other is optionally substituted C1-C6 alkyl, optionally substituted —C1-C4 alkylene-(C6-C10 aryl), or —RPEG1—O—(CH2CH2O)1-36—RPEG2, wherein RPEG1 is C1-C4 alkylene, and RPEG2 is —H or C1-C4 alkyl; and
the basic nitrogen atom bonded to Ra3 is optionally protonated; and
wherein R′ is hydrogen or —NO2 or other electron withdrawing group;
R45 is —CH2OH or —CO2H;
wherein —O′— represents the oxygen atom of an O-glycosidic bond cleavable by a glycosidase, wherein said cleavage within a drug linker moiety of a compound comprising the Ligand Drug Conjugate composition initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof that Ligand Drug Conjugate compound,
or
wherein the W is a Peptide Cleavable Unit for which the composition is represented by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
subscript P is 1, 2 or 3; and
subscript Q ranges from 1 to 6,
or is represented by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
R′ is hydrogen or —OC1-C6 alkyl or other electron donating group; and
and the remaining variable groups are as defined by the above structures in which W is a Glucuronide Unit,
wherein protease action on the Peptide Cleavable Unit cleaves the W—NH bond, wherein said cleavage within a drug linker moiety of a compound comprising the Ligand Drug Conjugate composition initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound.

### Claim 18 (depends on 15)

The Ligand Drug Conjugate composition of claim 15, wherein W is a Glucuronide Unit for which the composition is represented by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
subscript P is 1 or 2 or 3; and
subscript Q ranges from 1 to 6,
or is represented by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
Ra2 is hydrogen or C1-C6 alkyl;
BU is an acyclic Basic Unit having the structure of —[C(Ra1)(Ra1)]— [C(Ra1)(Ra1)]0-3—N(Ra3)(Ra3), wherein each Ra1 independently is hydrogen or C1-C4 alkyl, C6-C10 aryl, C5—C10 heteroaryl, (C6-C10 aryl)-C1-C4 alkyl-, or (C5-C10 heteroaryl)-C1-C4 alkyl-, optionally substituted, or two Ra1 together with the carbon(s) to which they are attached and any intervening carbons define an optionally substituted C3-C6 cycloalkyl; and
Ra3 independently are hydrogen, optionally substituted C1-C6 alkyl or Ra3 together with the nitrogen atom to which both are attached define a C3-C6 heterocyclyl in which the basic nitrogen atom is a skeletal atom,
or one of Ra3 is —H and the other is optionally substituted C1-C6 alkyl, optionally substituted —C1-C4 alkylene-(C6-C10 aryl), or —RPEG1—O—(CH2CH2O)1-36—RPEG2, wherein RPEG1 is C1-C4 alkylene, and RPEG2 is —H or C1-C4 alkyl; and
the basic nitrogen atom bonded to Ra1 is optionally protonated;
R′ is hydrogen or —NO2 or other electron withdrawing group;
R45 is —CH2OH or —CO2H; and
—O′— represents the oxygen atom of an O-glycosidic bond cleavable by a glycosidase, wherein said cleavage within a drug linker moiety of a compound comprising the Ligand Drug Conjugate composition initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound,
or wherein W is a Peptide Cleavable Unit for which the composition is represented by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
subscript P is 1, 2 or 3;
subscript Q ranges from 1 to 6,
or is represented by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
R′ is hydrogen or —OC1-C6 alkyl or other electron donating group; and
and the remaining variable groups are as defined by the above structures in which W is a Glucuronide Unit,
wherein protease action on the Peptide Cleavable Unit cleaves the W—NH bond, wherein said cleavage within a drug linker moiety of a compound comprising the Ligand Drug Conjugate composition initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound.

### Claim 19 (depends on 15)

The Ligand-Drug Conjugate composition of claim 15, wherein W is a Glucuronide Unit for which the composition is represented by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
R′ is hydrogen or —NO2 or other electron withdrawing group;
Ra2 is hydrogen or C1-C6 alkyl, optionally cyclized to BU, as indicated by the dotted curved line,
BU has the structure of —[C(Ra1)(Ra1)]—[C(Ra1)(Ra1)]0-3—N(Ra3)(Ra3),
wherein in the absence of cyclization to Ra2, each Ra1 independently is hydrogen or C1-C4 alkyl, C6-C10 aryl, C5-C10 heteroaryl, (C6-C10 aryl)-C1-C4 alkyl-, or (C5-C10 heteroaryl)-C1-C4 alkyl-, optionally substituted, or two Ra1 together with the carbon(s) to which they are attached and any intervening carbons define an optionally substituted C3-C6cycloalkyl; and
Ra3 independently are hydrogen, optionally substituted C1-C6 alkyl or Ra3 together with the nitrogen atom to which both are attached define a C3-C6 heterocyclyl in which the basic nitrogen atom is a skeletal atom,
or one of Ra3 is —H and the other is optionally substituted C1-C6 alkyl, optionally substituted —C1-C4 alkylene-(C6-C10 aryl), or —RPEG1—O—(CH2CH2O)1-36—RPEG2, wherein RPEG1 is C1-C4 alkylene, and RPEG2 is —H or C1-C4 alkyl; and
the basic nitrogen atom bonded to Ra3 is optionally protonated; and
in the presence of cyclization one of Ra1 or one of Ra3 is replaced with a bond to a carbon atom of Ra2 in which Ra2 is C1-C6 alkyl and the remaining Ra1 and Ra3 are as previously defined; and
wherein Y′ is —Xa—, —O—C(═O)—Xb— or —OC(═O)NH—CH2—Xa—,
wherein Xa or Xb are from TN, wherein —Xa— is O or S and Xb is —NH—; and
R45 is —CH2OH or —CO2H; and
wherein —O′— represents the oxygen atom of an O-glycosidic bond cleavable by a glycosidase, wherein said cleavage within a drug linker moiety of a compound comprising the Ligand Drug Conjugate composition initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound,
in particular, by the structure(s) of:
or a pharmaceutically acceptable salt thereof,
subscript P is 1, 2 or 3;
subscript Q ranges from 1 to 6; and
wherein the remaining variable groups are as previously defined,
more particularly, by the structure(s) of:
or a pharmaceutically acceptable salt thereof, wherein
the variable groups are as previously defined, or
the composition is represented particularly by the structure(s) of:
or a pharmaceutical acceptable salt thereof, wherein
the variable groups are as previously defined, or
wherein W is a Peptide Cleavable Unit for which the composition is represented by the structure(s) of:
or a pharmaceutically acceptable salt thereof, wherein
R′ is hydrogen or —OC1-C6 alkyl or other electron donating group; and
the remaining variable groups are as defined by the above structures in which W is a Glucuronide Unit; and
wherein protease action on the Peptide Cleavable Unit cleaves the W—NH bond, wherein said cleavage within a drug linker moiety of a compound of the Ligand Drug Conjugate composition initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound,
in particular by the structure(s) of:
or a pharmaceutically acceptable salt thereof,
more particularly by the structure(s) of:
or a pharmaceutically acceptable salt thereof, wherein the variable groups are as previously defined, or
the composition is represented particularly by the structure(s) of:
or a pharmaceutically acceptable salt thereof; and wherein the variable groups are as previously defined

### Claim 20 (depends on 15, 16, 17, 18, 19)

The Ligand-Drug Conjugate composition of any one of claims 15 to 19 in which W is a Peptide Cleavable Unit that Unit is comprised of a dipeptide wherein the dipeptide provides for a recognition site for a regulatory or lysosomal protease for cleavage by said protease of the W-J′ bond or the W—NH bond when J′ is —NH within a compound of the Ligand Drug Conjugate composition so as to initiate release of the NAMPT Drug Unit as NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound.

### Claim 21 (depends on 20)

The Ligand-Drug Conjugate composition of claim 20, wherein the W has the structure of:
wherein R34 is benzyl, methyl, isopropyl, isobutyl, sec-butyl, —CH(OH)CH3 or has the structure of
wherein the asterisk indicates the site of covalent attachment to the dipeptide backbone; and
R35 is methyl, —(CH2)4—NH2, —(CH2)3NH(C═O)NH2, —(CH2)3NH(C═NH)NH2, or, —(CH2)2CO2H; and
wherein the wavy lines indicate the points of covalent attachment of the dipeptide into the structure representing the Ligand-Drug Conjugate composition,
in particular W is selected from the group consisting of -Phe-Lys-, -Val-Ala-, -Val-Lys-, -Ala-Lys-, -Val-Cit-, -Phe-Cit-, -Leu-Cit-, -Ile-Cit-, -Phe-Arg-, and -Trp-Cit-, wherein Cit is citrulline.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15)

The Ligand-Drug Conjugate composition of any one of claims 1-13 and 15=19 wherein A or a subunit thereof is -LP(PEG)-,
wherein -LP- or a subunit thereof is a aminoalkanedioic acid, a diaminoalkanoic acid, a sulfur-substituted alkanedioic acid, a sulfur-substituted aminoalkanoic acid, a diaminoalkanol, an aminoalkanediol, a hydroxyl substituted alkanedioic acid, a hydroxyl substituted aminoalkanoic acid or a sulfur-substituted aminoalkanol residue, optionally substituted, wherein the substituted sulfur is in reduced or oxidized form, or
LP- or a subunit thereof is an amino acid residue of lysine, arginine, asparagine, glutamine, ornithine, citrulline, cysteine, homocysteine, penicillamine, threonine, serine, glutamic acid, aspartic acid, tyrosine, histidine or tryptophan, wherein the amino acid is in the D- or L-configuration, or
wherein -LP(PEG)- has the structure of:
or a pharmaceutical acceptable salt thereof, wherein
wherein subscript v is an integer ranging from 1 to 4;
XLP is selected from the group consisting of —O—, —NRLP—, —S—, —S(═O)—, —S(═O)2—, —C(═O)—, —C(═O)N(RLP)—, —N(RLP)C(═O)N(RLP)—, —N(RLP)C(═NRLP)N(RLP)—, and C3-C8 heterocyclo, in particular —O—, —NH, —S— and —C(═O)—;
wherein each RLP is independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl, or two of RLP together along with the carbons atoms to which they are attached and their intervening atoms define a C5-C6 heterocyclo and any remaining RLP are as previously defined;
Ar is a C6-C10 arylene or a C5-C10 heteroarylene, optionally substituted;
each RE and RF is independently selected from the group consisting of —H, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkylene, optionally substituted C6-C10 arylene and optionally substituted C5-C10 heteroarylene, in particular hydrogen and C1-C4 alkyl,
or RE and RF together with the carbon atom to which both are attached defines an optionally substituted spiro C3-C6 carbocyclo, or RE and RF from adjacent carbon atoms together with these atoms and any intervening carbon atoms defines an optionally substituted C5-C6 carbocyclo with any remaining RE and RF as previously defined, or
wherein the side chain of —[C(RE)(RF)]v—XLP— is provided by a natural or un-natural amino acid side chain; and
wherein the wavy lines indicate the sites of covalent attachments within the remainder of the Conjugate structure;
in particular having the PEG Unit represented by:
wherein the wavy line indicates site of attachment to XLP of the Parallel Connector Unit (LP);
subscript n′ independently ranges from 1 to 72;
RPEG1 is an optional PEG Attachment Unit;
RPEG2 is a PEG Capping Unit; and
RPEG3 is an PEG Coupling Unit, or
having XLP—PEG with the structure of:
wherein subscript n′ is 8, 12 or 24 and RPEG2 is H or —CH3.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19)

The Ligand-Drug Conjugate composition of any one of claims 1-13 and 15-19, wherein A or a subunit thereof has the structure of formula (3) or formula (4):
wherein the wavy lines indicated covalent attachment within the composition structure;
wherein K and L′ independently are C, N, O or S, provided that when K or L′ is 0 or S, R41 and R42 to K or R43 and R44 to L′ are absent, and when K or L′ are N, one of R41, R42 to K or one of R42, R43 to L′ are absent, and provided that no two adjacent L′ are independently selected as N, O, or S;
wherein subscripts e and f are independently selected integers that range from 0 to 12, and subscript g is an integer ranging from 1 to 12;
wherein G is hydrogen, optionally substituted C1-C6 alkyl, —OH, —ORPR, —CO2H, CO2RPR, wherein RPR is a suitable protecting, or
G is —N(RPR)(RPR), wherein RPR are independently a protecting group or RPR together form a suitable protecting group, or
G is —N(R45)(R46), wherein one of R45, R46 is hydrogen or RPR, wherein RPR is a suitable protecting group, and the other is hydrogen or optionally substituted C1-C6 alkyl;
wherein R38 is hydrogen or optionally substituted C1-C6 alkyl;
R39-R44 are independently selected from the group consisting of hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, and optionally substituted heteroaryl,
or R39, R40 together with the carbon atom to which both are attached, or R41, R42 together with K to which both are attached when K is a carbon atom, define a C3-C6 carbocyclo, and R41-R44 are as defined herein,
or R43, R44 together with L′ to which both are attached when L′ is a carbon atom define a C3-C6 carbocyclo, and R39-R42 are as defined herein,
or R40 and R41, or R40 and R43, or R41 and R43 to together with the carbon atom or heteroatom to which both are attached and the atoms intervening between those carbon atoms and/or heteroatoms define a C5-C6 carbocyclo or a C5-C6 heterocyclo, and R39, R44 and the remainder of R40-R43 are as defined herein,
provided that when K is O or S, R41 and R42 are absent, and when K is N, one of R41, R42 is absent, and when L′ is O or S, R43 and R44 are absent, and when L′ is N, one of R43, R44 is absent, or
A or a subunit thereof is an alpha-amino, beta-amino or another amine-containing acid residue,
in particular, wherein formula (3) or formula (4) has the structure of formula (3a) or formula (4a):
wherein subscript e and f are independently 0 or 1.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19)

The Ligand-Drug Conjugate composition of any one of claims 1-13 and 15-19 wherein the Ligand Unit is an antibody or an antigen-binding fragment thereof, thereby defining an antibody Ligand Unit of an antibody drug conjugate (ADC),
wherein the antigen targeted by the antibody Ligand Unit is an accessible cell-surface antigen of abnormal cells that is capable of cellular internalization when bound to an ADC compound of the composition and is present in greater copy number on the abnormal cells in comparison to normal cells distant from the site of the abnormal cells, or the antigen is an accessible cell-surface antigen of a vascular epithelial cell in the vicinity of normal cells, wherein said antigen is capable of cellular internalization of bound ADC and is present in greater copy number on said cells in comparison to normal epithelial cells distant from the site of the abnormal cells.

### Claim 25 (depends on 24)

The Ligand Drug Conjugate composition claim 24, wherein subscript p is about 2, about 4, about 8, or about 10.

### Claim 26 (depends on 15, 16, 17, 18, 19)

The Ligand Drug Conjugate composition of any one of claim 15-19, wherein the sulfur atom attached to the indicated succinimide (M2) or succinic acid amide (M3) moeity of a drug linker moiety of the Conjugate is that of an antibody or antigen-binding fragment thereof, thereby defining an antibody Ligand Unit, wherein the sulfur atom of the antibody Ligand Unit bonded to the succinic acid (M2) moiety or succinic acid amide (M3) moiety is that of a cysteine residue native to the antibody or antigen-binding fragment thereof or an introduced cysteine residue in the heavy chain or light chain of the antibody or antigen binding-fragment thereof.

### Claim 27 (depends on 1)

The Ligand Drug Conjugate composition of claim 1, wherein the composition is represent by the structure(s) of:
or pharmaceutical acceptable salt(s) thereof,
or
the composition is represent by the structure(s) of:
or pharmaceutical acceptable salt(s) thereof, wherein
or
the composition is represent by the structure(s) of:
or pharmaceutical acceptable salt(s) thereof,
in particular by:
or pharmaceutical acceptable salt(s) thereof,
wherein
subscript a is 1 and A is an amino acid residue;
BU is a acyclic Basic Unit so that the dotted curve line is absent, and Ra2 is hydrogen, or BU together with Ra2 as C1-C6 alkyl and the carbon atom to which both are attached define a cyclic Basic Unit so that the dotted curved line is present; and
R′ is hydrogen or —NO2,
more particularly by:
or pharmaceutical acceptable salt(s) thereof,
or by:
or pharmaceutical acceptable salt(s) thereof,
wherein
L is an antibody, thereby defining an antibody Ligand Unit of an antibody drug conjugate (ADC), and S is a sulfur atom of the antibody, wherein the antibody is a monoclonal antibody in particular a humanized or chimeric antibody.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 27)

A formulation comprising a Ligand Drug Conjugate composition of any one of claims 1-13, 15-19 and 27 and at least one, two, three or more excipients,
in particular, wherein the formulation is a pharmaceutically acceptable formulation or a precursor thereof, particularly wherein the pharmaceutically acceptable formulation precursor is a solid suitable for reconstitution as a solution for intravenous injection to a subject in need thereof, or the pharmaceutically acceptable formulation is a liquid suitable for intravenous injection to a subject in need thereof, more particularly in which the Ligand Drug Conjugate composition is present in an effective amount for treatment of a hyperproliferative disease or condition in said solid or liquid formulation.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 27)

A method of treating a hyperproliferative disease or condition comprising the step of administering to a subject in need thereof having said disease or condition, in particular having a cancer, more particularly a leukemia or lymphoma, an effective amount of a Ligand Drug Conjugate composition of any one of claims 1-13, 15-19 and 27.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 27)

A method of inhibiting the multiplication of a tumor cell or cancer cell, or causing apoptosis in a tumor cancer cell by exposing said cell to an effective amount of a Ligand Drug Conjugate composition or a compound thereof of any one of claims 1-13, 15-19 and 27.

### Claim 31

A Drug Linker compound, wherein the compound is represented by the structure of:
or a salt thereof, wherein
LR is a primary linker having a functional group capable interacting with a targeting agent to form a covalent bond to a Ligand Unit corresponding to or incorporating the targeting agent in a Ligand Drug Conjugate composition;
D is a NAMPT Drug Unit represented by the general structure of:
or a salt thereof, wherein
the wavy line indicates the site of covalent attachment to LO, as indicated, which is an optional secondary linker, or LR, depending on the presence or absence of LO, respectively;
HN is a NAMPT Head Unit, wherein the NAMPT Head Unit is a C5-C24 heteroaryl or partially aromatic C9-C24 heterocyclyl, optionally substituted, wherein the C5-C24 heteroaryl or partially aromatic C9-C24 heterocyclyl is comprised of an optionally substituted 5- or 6-membered nitrogen-containing heteroaromatic ring system corresponding to the heterocycle of nicotinamide, and is capable of interacting with enzymatically competent NAMPT homodimer at its nicotinamide mononucleotide binding site when the NAMPT Drug Unit is released from a Ligand Drug Conjugate compound of the composition as a NAMPT inhibitor (NAMPTi) compound or derivative thereof;
DA is a Donor-Acceptor Unit wherein the Donor-Acceptor Unit is or is comprised of a hydrogen bond donor acceptor functional group and is bonded to a carbon skeletal atom at position 2 or 3 of the 5-membered nitrogen-containing heteroaromatic ring system or at position 3 or 4 of the 6-membered nitrogen-containing heteroaromatic ring system, with optional formal cyclization of DA back to an adjacent skeletal carbon atom of the 6-membered nitrogen-containing heteroaromatic ring system through an introduced optionally substituted non-aromatic carbon atom or an optionally substituted nitrogen, oxygen or sulfur atom resulting in a partially aromatic or fully aromatic fused 6,5- or 6,6-ring system,
wherein said bonding of DA is in relation to a skeletal nitrogen atom of the 5- or 6 membered nitrogen-containing heteroaromatic ring system and wherein said formal cyclization to the adjacent carbon atom of the 6-membered nitrogen-containing heteroaromatic ring system substantially retains the hydrogen bonding capability of the donor acceptor functional group of DA in absence of said cyclization;
IN is an Interconnecting Unit, wherein the Interconnecting Unit is or is comprised of —X1—[C(═O)]0,1—, —X1—S(═O)1,2-, —X2—C6-C24 arylene-[C(═O)]0,1—, —X2—C6-C24 arylene-[S(═O)1,2]0,1, —X2—C6-C24 arylene-O—, —X2—C5-C24 heteroarylene-[C(═O)0,1]—, —X2—C5-C24 heteroarylene-[S(═O)1,2]0,1, —X2—C5-C24 heteroarylene-O— or —X2—C3-C20 heterocyclo-[C(═O)0,1]—, wherein the arylene, heteroarylene and heterocyclo are optionally substituted;
X1 is optionally substituted C5-C7 alkylene;
X2 is absent or is an optionally substituted C1-C4 alkylene;
TN is a NAMPT Tail Unit, wherein the NAMPT Tail Unit is or is comprised of an optionally substituted amino-alcohol residue or a carboxylic acid-alcohol residue, the —O— or optionally substituted nitrogen of which is the site of covalent attachment to LO, or LR, depending on the presence or absence of LO, or
TN is or is comprised of an optionally substituted benzamide moiety, the amide nitrogen atom of which is bonded to IN with optional cyclization of that atom back to IN or to the remainder of TN, and the aromatic ring of which is at least substituted with a hydroxyl, thiol or amino residue, the —O—, —S— or optionally substituted nitrogen atom of which at position 3 or 4 relative to the site at which the amide carbonyl carbon atom is attached is the site of covalent attachment to LO or LR, depending on the presence or absence of LO, or
TN is or is comprised of an optionally substituted aryl or biaryl moiety, an aromatic skeletal atom of which is bonded to IN, or to the remainder of TN, and wherein an aromatic ring of which is at least substituted with a hydroxyl, thiol or an amino residue, the —O—, —S— or optionally substituted nitrogen of which is the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively; and
wherein TN or the remainder thereof is bonded to IN, wherein said remainder is an optionally substituted C2-C7 heteroalkylene or an optionally substituted C5-C6 heterocyclo,
subscripts a and b independently are 0 or 1, indicating the absence or presence, respectively, of A or B;
subscript n is 1, 2, 3 or 4;
A is an first optional Stretcher; and
B is a Branching Unit, when subscript b is 1 and subscript n is 2, 3 or 4, or B is absent, so that subscript b is 0, when subscript n is 1,
wherein each of A and B is an independently selected single unit or is optionally comprised or consists of at least two, three or four independently selected subunits;
subscript y is 0, 1 or 2, indicating the absence or presence of one or two of Y, respectively;
Y is a Spacer Unit; and subscript y is 0, 1 or 2, indicating the absence or presence of one or two of Y, respectively,
provided that when subscript y is 1, Y is a Spacer Unit covalently attached to a heteroatom or moiety thereof of TN selected from the group consisting of —O—, —S— and optionally substituted nitrogen,
provided that when subscript y is 2 so that Yy is —Y—Y, Y is a first Spacer Unit and Y′ is a second Spacer Unit or a functional group comprised of the optionally substituted heteroatom from TN; and
provided that subscript y is 1 or 2 when W is a Glucuronide Unit of formula Y(W′), in which instance subscript y is inclusive of a first Spacer Unit Y, wherein that Spacer Unit is a required self-immolative Spacer Unit; and
subscript w is 0 or 1, indicating the absence or presence, respectively, of W; wherein
when subscript w is 1, W is a Peptide Cleavable Unit or said Glucuronide Unit in which W′ represents a carbohydrate moiety with glycosidic bonding to the required self-immolative Spacer Unit through an optionally substituted heteroatom, enzymatic or non-enzymatic cleavage of that Unit in the Drug Linker Compound, or in a drug linker moiety of a Ligand Drug Conjugate compound or a N-acetyl-cysteine (NAC)conjugate prepared from the Drug Linker compound initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative therefrom, and
when subscript w is 0, which indicates the absence of a Cleavable Unit, enzymatic or non-enzymatic cleavage of the bond between the indicated LR and LO moieties, when LO is present, or the bond between LR and D, when LO is absent, initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from the Drug Linker compound or said drug linker moiety or NAC conjugate.

### Claim 32 (depends on 31)

The Drug Linker compound of claim 31, wherein the NAMPT Head (HN) Unit is a pyridine mimetic.

### Claim 33 (depends on 31)

The Drug Linker compound of claim 31, wherein the Donor Acceptor (DA) Unit is comprised of an optionally substituted amide functional group or bioisostere thereof.

### Claim 34 (depends on 31)

The Drug Linker compound of claim 31, wherein HN-DA is a nicotinamide mimetic.

### Claim 35 (depends on 31)

The Drug Linker compound of claim 31, wherein the 6-membered nitrogen-containing heteroaromatic ring system of HN is that of pyridine with optional cyclization of DA back to the pyridine aromatic ring system through an introduced aromatic oxygen, sulfur or an optionally substituted nitrogen atom so that HN contains a 6-5 fused aromatic ring system.

### Claim 36 (depends on 31)

The Drug Linker compound of claim 31, wherein each of the NAMPT homodimers of the enzymatically competent NAMPT homodimer has the amino acid sequence of SEQ ID 1.

### Claim 37 (depends on 31)

The Drug Linker compound of claim 31, wherein the NAMPT Head Unit has the structure of:
or a salt thereof,
in particular, having the structure of:
or a salt thereof, wherein
R1 is hydrogen, —NH2 or chloro;
R2 is fluoro;
R3 is hydrogen or —NH2; and
the wavy line indicates the site of covalent attachment to DA and an adjacent aromatic carbon atom thereto is the site of said optional cyclization by DA to HN.

### Claim 38 (depends on 31)

The Drug Linker compound of claim 31, wherein the Donor-Acceptor Unit has the structure of:
in particular, having the structure of:
wherein R4 is hydrogen or optionally substituted C1-C4 alkyl;
DA is optionally cyclized to HN, wherein said cyclization is to the sp2 carbon atom proximal to the carbonyl carbon (as indicated) through an introduced optionally substituted non-aromatic carbon atom or an optionally substituted aromatic heteroatom;
the wavy line indicates the site of covalent attachment to HN, and the carbon atom adjacent thereto is the site of said optional cyclization by DA; and
the pound sign (#) indicates the site of covalent attachment to IN, or
wherein the Donor-Acceptor Unit has the structure of:
or a salt thereof,
in particular, having the structure of:
or a salt thereof, wherein
XD is O, S or NRD, wherein the nitrogen atom is optionally protonated and RD is hydrogen or optionally substituted C1-C4 alkyl;
each R4 is independently selected from the group consisting of hydrogen and optionally substituted C1-C4 alkyl, or both R4 together with the nitrogen atoms to which they are attached and the intervening carbon atom(s) define an optionally substituted C5-C6 heterocyclo;
the pound sign (#) indicates the site of covalent attachment to IN; and the wavy line indicates the site of covalent attachment to HN,
wherein DA is optionally cyclized back to an adjacent aromatic carbon atom of HN, wherein said cyclization is from the indicated nitrogen atom so that R4 bonded thereto is replaced by a covalent bond to said adjacent aromatic carbon atom, or is from XD when XD is —NRD, either directly or through an introduced —S(═O)0-2 moeity, in which either instance RD is replaced by a bond to said adjacent carbon atom or the sulfur atom of said introduced moiety.

### Claim 39 (depends on 31)

The Drug Linker compound of claim 31, wherein HN-DA- has the structure of:
or a salt thereof, wherein
R4 is hydrogen or optionally substituted C1-C4 alkyl; and
the wavy line indicates the site of covalent attachment to IN, and
wherein the sp2 carbon atom proximal to the carbonyl carbon atom is the site (as indicated) of optional cyclization to HN through an introduced optionally substituted non-aromatic carbon atom or an optionally substituted aromatic heteroatom.

### Claim 40 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39)

The Drug Linker compound of any one of claims 31 to 39, wherein the NAMPT Tail Unit is or is comprised of an optionally substituted amino alcohol moeity,
wherein the oxygen atom of the alcohol is the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively,
in particular having the structure of.
or a pharmaceutically acceptable salt thereof, wherein
R4 is hydrogen or optionally substituted C1-C4 alkyl;
the wavy line indicates the site of covalent attachment to IN; and
the pound sign (#) indicates the site of covalent to LO or LR, depending on the presence or absence of LO, respectively, or
wherein the Tail Unit is or is comprised of an optionally substituted benzamide moeity having a functional group providing a heteroatom that is the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively,
in particular, having the structure of:
wherein Xb is —S— —O— or —NH—, optionally substituted; and
R4 is hydrogen or optionally substituted C1-C4 alkyl, wherein
the benzamide moeity is optionally cyclized to IN, wherein the amide nitrogen atom of the benzamide moiety is the site of said cyclization so that R4 is replaced by a covalent bond to IN,
more particularly, having the structure of:
wherein the wavy line indicates the site of covalent attachment to IN;
the pound sign (#) indicates the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively.

### Claim 41 (depends on 40)

The Drug Linker compound of claim 40, wherein IN is —CH2—(CH2)3-7—CH2—, —CH2—(CH2)3-7—CH2—O—, —CH2—(CH2)3-7—C(═O)—, —CH2—(CH2)3-7—S(═O)2— or —CH2—(CH2)3-7—S(═O)—.

### Claim 42 (depends on 41)

The Drug Linker compound of claim 41, wherein —IN-TN- has the structure of:
wherein Xb is —NH—, —O— or —S—;
the wavy line indicates the site of covalent attachment to DA; and
the pound sign (#) indicates the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively.

### Claim 43 (depends on 31)

The Drug Linker compound of claim 31, wherein the NAMPT Drug Unit has the structure of:
or a salt thereof, wherein
the pound sign (#) indicates the site of covalent attachment to LO or LR, depending on the presence or absence of LO, respectively.

### Claim 44 (depends on 31)

The Drug Linker compound of claim 31, wherein the Drug Linker compound is represented by the structure of:
or a salt thereof, wherein
R6 is hydrogen or an optionally substituted C1-C6 alkyl, which in Formula 2 is bonded to the saturated carbon atom adjacent to the carbon substituted by L-S—;
AO is a second optional Stretcher Unit;
BU is a Basic Unit and Ra2 is an optionally substituted C1-C12 alkyl group; and
the dotted curved line indicates optional cyclization so that in the absence of said cyclization BU is an acyclic Basic Unit or in the presence of said cyclization BU is a cyclized Basic Unit in which Ra2 and BU together with the carbon atom to which both are attached, define an optionally substituted spiro C3-C20 heterocyclo containing a skeletal basic nitrogen atom of a secondary or tertiary amine functional group as the basic function group of the cyclic Basic Unit,
wherein the basic nitrogen atom of the acyclic Basic Unit or cyclic Basic Unit is optionally suitably protected by a nitrogen protecting group, dependent on the degree of substitution of the basic nitrogen atom, or is optionally protonated,
in particular, having the structure of:
wherein [HE] as AO is an optional Hydrolysis Enhancing Unit;
subscript w is 1;
W is Peptide Cleavable Unit; and
the remaining variable groups retain their previous meanings
wherein protease action on the Peptide Cleavable Unit resulting in cleavage of the W-J′ bond within the Drug Linker compound, or from the drug linker moiety of the Ligand Drug Conjugate compound or N-acetyl-cysteine (NAC) conjugate prepared from the Drug Linker compound initiates release of the NAMPT Drug Unit as NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound, or
W is a Glucuronide Unit of formula —Y(W′)— having the structure of:
wherein Su is a carbohydrate moiety and -E′- represents an optionally substituted heteroatom of an glycosidic bond cleavable by a glycosidase so that Su-E′ is W′ and the remainder of the Glucuronide Unit structure is a self-immolative Spacer Unit bonded to W′;
J′ is an independently selected heteroatom, optionally substituted, and the wavy line thereto is the site of covalent attachment resistant to enzymatic or non-enzymatic cleavage under normal physiological conditions wherein said site of covalent attachment is to A when subscript a is 1 or to the indicated LSS primary linker when subscript a is 0; and
V, Z1, Z2 and Z3 are independently ═N— or ═C(R24)—, wherein each R24 is independently selected from the group consisting of hydrogen and C1-C12 alkyl, C2-C12 alkenyl and C2-C12 alkynyl, optionally substituted, and halogen, an electron withdrawing group, an electron donating group, -E′-Su, and —C(R8)(R9)—,
provided that one and only one —C(R8)(R9)— moiety and one and only one -E′-Su moiety is present,
wherein one of V, Z1, Z2 and Z3 is ═C(R24)— in which R24 is —C(R8)(R9)— and another of V, Z1, Z2 and Z3 is ═C(R24)— in which R24 is -E′-Su,
provided the —C(R8)(R9)— and -E′-Su moieties are ortho or para to each other;
R8 and R9 independently are hydrogen, or C1-C12 alkyl, C2-C12 alkenyl or C2-C12 alkynyl, optionally substituted, or C6-C20 aryl or C5-C20 heteroaryl, optionally substituted, or
R8 and R9 together with the carbon atom to which both are attached define an optionally substituted C5-C20 carbocyclo; and
R′ is hydrogen or —NO2, or other electron withdrawing group or —OC1-C6 alkyl, or other electron donating group; and
wherein the wavy line adjacent to the —C(R8)(R9)— moiety indicates the site of covalent attachment of the Glucuronide Unit to Y′ when subscript y is 2, or to D when subscript y is 1, and
wherein the remaining variable groups of the Drug Linker compound are as previously defined for W as a Peptide Cleavable Unit;
and
wherein glycosidase action on the Glucuronide Unit resulting in cleavage of its glycosidic bond initiates release of the NAMPT Drug Unit as NAMPTi compound or derivative thereof from the Drug Linker compound or from the drug linker moiety of the Ligand Drug Conjugate compound or N-acetyl-cysteine (NAC) conjugate prepared from the Drug Linker compound.

### Claim 45 (depends on 44)

The Drug Linker compound of claim 44, wherein W is a Glucuronide Unit for which —W—Yy-D has the structure of:
or a salt thereof, wherein
Xa is a nitrogen atom from a primary or secondary amine functional group of TN;
Xb is an oxygen atom from an alcohol functional group or a sulfur atom from a thiol functional group of TN,
or —W—Yy-D has the structure of:
or a salt thereof,
R51, R52 and R53 independently are hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C6-C14 aryl, or optionally substituted C-linked C3-C8 heteroaryl,
or R51 and R52 together with the nitrogen and carbon atoms to which both are attached define an azetidine, pyrrolidine, piperidine or homopiperidine heterocyclo, and R53 is hydrogen;
and in either —W—Yy-D structure:
R45 is —CH2OH or —CO2H;
R′ is hydrogen or —NO2 or other electron withdrawing group;
J′ is an optionally substituted heteroatom, and the wavy line thereto is the site of covalent attachment resistant to enzymatic or non-enzymatic cleavage under normal physiological conditions; and
wherein O* represents the oxygen atom from an alcohol functional group of TN and O′ represents the oxygen atom of an O-glycosidic bond cleavable by a glycosidase,
wherein said cleavage initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative from the Drug Linker compound or from the drug linker moiety of the Ligand Drug Conjugate compound or N-acetyl-cysteine (NAC) conjugate prepared from the Drug Linker compound,
or wherein
W is a Peptide Cleavable Unit for which —Yy-D- has the structure of:
or a salt thereof, wherein
Xa is an oxygen atom from an alcohol functional group or a sulfur atom of a thiol functional group of TN;
Xb is a nitrogen atom from a primary or secondary amine functional group of TN, or has the structure of:
or a salt thereof, wherein
R′ is hydrogen or —OC1-C6 alkyl or other electron donating group;
R7, R10 and R11 independently are hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C6-C14 aryl, or optionally substituted C-linked C3-C8 heteroaryl,
or R7 and R10 together with the nitrogen and carbon atoms to which both are attached define an azetidine, pyrrolidine, piperidine or homopiperidine heterocyclo, and R11 is hydrogen;
and
R45 is —CH2OH or —CO2H;
O* represents the oxygen atom from an alcohol functional group of TN; and
J′ is an optionally substituted heteroatom bonded to W as indicated by the wavy line, wherein cleavage of that bond initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative from the Drug Linker compound or from the drug linker moiety of the Ligand Drug Conjugate compound or N-acetyl-cysteine (NAC) conjugate prepared from the Drug Linker compound.

### Claim 46 (depends on 44)

The Drug Linker compound of claim 44, wherein W is a Glucuronide Unit for which the Drug linker compound is represented by the structure of:
or a salt thereof, wherein
subscript P is 1, 2 or 3; and
subscript Q ranges from 1 to 6,
or by the structure of:
or a pharmaceutical acceptable salt thereof, wherein
Ra2 is hydrogen or C1-C6 alkyl;
BU is an acyclic Basic Unit having the structure of —[C(Ra1)(Ra1)]— [C(Ra1)(Ra1)]0-3—N(Ra3)(Ra3), wherein each Ra1 independently is hydrogen or C1-C4 alkyl, C6-C10 aryl, C5-C10 heteroaryl, (C6-C10 aryl)-C1-C4 alkyl-, or (C5-C10 heteroaryl)-C1-C4 alkyl-, optionally substituted, or two Ra1 together with the carbon(s) to which they are attached and any intervening carbons define an optionally substituted C3-C6 cycloalkyl; and
Ra3 independently are hydrogen, optionally substituted C1-C6 alkyl or Ra3 together with the nitrogen atom to which both are attached define a C3-C6 heterocyclyl in which the basic nitrogen atom is a skeletal atom,
or one of Ra3 is —H and the other is optionally substituted C1-C6 alkyl, optionally substituted —C1-C4 alkylene-(C6-C10 aryl), or —RPEG1—O—(CH2CH2O)1-36—RPEG2, wherein RPEG1 is C1-C4 alkylene, and RPEG2 is —H or C1-C4 alkyl; and
the basic nitrogen atom bonded to Ra1 is optionally protonated; and
wherein R′ is hydrogen or —NO2 or other electron withdrawing group;
R45 is —CH2OH or —CO2H;
wherein —O′— represents the oxygen heteroatom of an O-glycosidic bond cleavable by a glycosidase, wherein said cleavage within initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative from the Drug Linker compound or from the drug linker moiety of the Ligand Drug Conjugate compound or N-acetyl-cysteine (NAC) conjugate prepared from the Drug Linker compound, or
wherein the W is a Peptide Cleavable Unit for which the composition is represented by the structure of:
or a salt thereof, wherein
subscript P is 1, 2 or 3; and
subscript Q ranges from 1 to 6,
or is represented by the structure of:
or a salt thereof, wherein
R′ is hydrogen or —OC1-C6 alkyl or other electron donating group; and
the remaining variable groups are as defined by the above structures in which W is a Glucuronide Unit, and
wherein protease action on the Peptide Cleavable Unit cleaves the W—NH bond, wherein said cleavage initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative from the Drug Linker compound or from the drug linker moiety of the Ligand Drug Conjugate compound or N-acetyl-cysteine (NAC) conjugate prepared from the Drug Linker compound.

### Claim 47 (depends on 44)

The Drug Linker compound of claim 44, wherein W is a Glucuronide Unit for which the Drug Linker compound is represented by the structure of:
or a salt thereof, wherein
subscript P is 1, 2 or 3; and
subscript Q ranges from 1 to 6,
or is represented by the structure of:
or a salt thereof, wherein
Ra2 is hydrogen or C1-C6 alkyl;
BU is an acyclic Basic Unit having the structure of —[C(Ra1)(Ra1)]—[C(Ra1)(Ra1)]0-3—N(Ra3)(Ra3), wherein each Ra1 independently is hydrogen or C1-C4 alkyl, C6-C10 aryl, C5-C10 heteroaryl, (C6-C10 aryl)-C1-C4 alkyl-, or (C5-C10 heteroaryl)-C1-C4 alkyl-, optionally substituted, or two Ra1 together with the carbon(s) to which they are attached and any intervening carbons define an optionally substituted C3-C6 cycloalkyl; and
Ra3 independently are hydrogen, optionally substituted C1-C6 alkyl or Ra3 together with the nitrogen atom to which both are attached define a C3-C6 heterocyclyl in which the basic nitrogen atom is a skeletal atom,
or one of Ra3 is —H and the other is optionally substituted C1-C6 alkyl, optionally substituted —C1-C4 alkylene-(C6-C10 aryl), or —RPEG1—O—(CH2CH2O)1-36—RPEG2, wherein RPEG1 is C1-C4 alkylene, and RPEG2 is —H or C1-C4 alkyl; and
the basic nitrogen atom bonded to Ra1 is optionally protonated;
R′ is hydrogen or —NO2 or other electron withdrawing group;
R45 is —CH2OH or —CO2H; and
wherein —O′— represents the oxygen atom of an O-glycosidic bond cleavable by a glycosidase, wherein said cleavage initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from the Drug Linker compound or from the drug linker moiety of the Ligand Drug Conjugate compound or N-acetyl-cysteine (NAC) conjugate prepared from the Drug Linker compound,
or
wherein W is a Peptide Cleavable Unit for which the Drug Linker compound is represented by the structure of:
or a salt thereof, wherein
subscript P is 1, 2 or 3;
subscript Q ranges from 1 to 6,
or is represented by the structure of:
wherein
R′ is hydrogen or —OC1-C6 alkyl or other electron donating group; and
and the remaining variable groups are as defined by the above structures in which W is a Glucuronide Unit; and
wherein protease action on the Peptide Cleavable Unit cleaves the W—NH bond, wherein said cleavage initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from the Drug Linker compound or from the drug linker moiety of the Ligand Drug Conjugate compound or N-acetyl-cysteine (NAC) conjugate prepared from the Drug Linker compound.

### Claim 48 (depends on 44)

The Drug Linker compound of claim 44, wherein W is a Glucuronide Unit for which the Drug Linker compound is represented by the structure of:
or a salt thereof, wherein
or a pharmaceutical acceptable salt thereof, wherein
R′ is hydrogen or —NO2 or other electron withdrawing group;
Ra2 is hydrogen or C1-C6 alkyl, optionally cyclized to BU, as indicated by the dotted curved line,
BU has the structure of —[C(Ra1)(Ra1)]—[C(Ra1)(Ra1)]0-3—N(Ra3)(Ra3),
wherein in the absence of cyclization to Ra2, each Ra1 independently is hydrogen or C1-C4 alkyl, C6-C10 aryl, C5-C10 heteroaryl, (C6-C10 aryl)-C1-C4 alkyl-, or (C5-C10 heteroaryl)-C1-C4 alkyl-, optionally substituted, or two Ra1 together with the carbon(s) to which they are attached and any intervening carbons define an optionally substituted C3-C6 cycloalkyl; and
Ra3 independently are hydrogen, optionally substituted C1-C6 alkyl or Ra3 together with the nitrogen atom to which both are attached define a C3-C6 heterocyclyl in which the basic nitrogen atom is a skeletal atom,
or one of Ra3 is —H and the other is optionally substituted C1-C6 alkyl, optionally substituted —C1-C4 alkylene-(C6-C10 aryl), or —RPEG1—O—(CH2CH2O)1-36—RPEG2, wherein RPEG1 is C1-C4 alkylene, and RPEG2 is —H or C1-C4 alkyl; and
the basic nitrogen atom bonded to Ra3 is optionally protonated; and
in the presence of cyclization one of Ra1 or one of Ra3 is replaced with a bond to a carbon atom of Ra2 in which Ra2 is C1-C6 alkyl and the remaining Ra1 and Ra3 are as previously defined; and
wherein Y′ is —Xa—, —O—C(═O)—Xb— or —OC(═O)NH—CH2—Xa—,
wherein Xa or Xb are from TN, wherein —Xa— is O or S and Xb is —NH—; and
R45 is —CH2OH or —CO2H,
in particular, by the structure of:
or a salt thereof, wherein
subscript P is 1, 2 or 3;
subscript Q ranges from 1 to 6; and
wherein the remaining variable groups are as previously defined,
more particularly, by the structure of:
or a salt thereof,
or in particular by the structure of:
or a salt thereof, wherein
the variable groups are as previously defined, or
wherein W is a Peptide Cleavable Unit for which the Drug Linker compound is represented by the structure of:
or a salt thereof, wherein
R′ is hydrogen or —OC1-C6 alkyl or other electron donating group; and
the remaining variable groups are as defined by the above structures in which W is a Glucuronide Unit; and
wherein protease action on the Peptide Cleavable Unit cleaves the W—NH bond, wherein said cleavage within a drug linker moiety of a compound of the Ligand Drug Conjugate composition initiates release of the NAMPT Drug Unit as a NAMPTi compound or derivative thereof from that Ligand Drug Conjugate compound,
in particular by the structure of:
or a salt thereof, more particularly by the structure of:
or a salt thereof, or particular by the structure of:
or a salt thereof; and wherein and wherein the variable groups are as previously defined.

### Claim 49 (depends on 44, 45, 46, 47, 48)

The Drug Linker compound of any one of claims 44 to 48 in which W is a Peptide Cleavable Unit that Unit is comprised of a dipeptide wherein the dipeptide provides for a recognition site for a regulatory or lysosomal protease for cleavage by said protease of the W-J′ bond or the W—NH bond when J′ is —NH within the Drug Linker compound or the drug linker moiety of the Ligand Drug Conjugate compound or N-acetyl-cysteine (NAC) conjugate prepared from the Drug Linker compound so as to initiate release of the NAMPT Drug Unit as NAMPTi compound or derivative from that Drug Linker compound, drug linker moiety or NAC conjugate.

### Claim 50 (depends on 49)

The Drug Linker compound of claim 49, wherein the W has the structure of:
wherein R34 is benzyl, methyl, isopropyl, isobutyl, sec-butyl, —CH(OH)CH3 or has the structure of
wherein the asterisk indicates the site of covalent attachment to the dipeptide backbone; and
R35 is methyl, —(CH2)4—NH2, —(CH2)3NH(C═O)NH2, —(CH2)3NH(C═NH)NH2, or, —(CH2)2CO2H; and
wherein the wavy lines indicate the points of covalent attachment of the dipeptide into the structure representing the Ligand-Drug Conjugate composition,
in particular W is selected from the group consisting of -Phe-Lys-, -Val-Ala-, -Val-Lys-, -Ala-Lys-, -Val-Cit-, -Phe-Cit-, -Leu-Cit-, -Ile-Cit-, -Phe-Arg-, and -Trp-Cit-, wherein Cit is citrulline.

### Claim 51 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The Drug Linker compound of any one of claims 31-48, wherein A or a subunit thereof is -LP(PEG)-,
wherein -LP- or a subunit thereof is a aminoalkanedioic acid, a diaminoalkanoic acid, a sulfur-substituted alkanedioic acid, a sulfur-substituted aminoalkanoic acid, a diaminoalkanol, an aminoalkanediol, a hydroxyl substituted alkanedioic acid, a hydroxyl substituted aminoalkanoic acid or a sulfur-substituted aminoalkanol residue, optionally substituted, wherein the substituted sulfur is in reduced or oxidized form, or
-LP- or a subunit thereof is an amino acid residue of lysine, arginine, asparagine, glutamine, ornithine, citrulline, cysteine, homocysteine, penicillamine, threonine, serine, glutamic acid, aspartic acid, tyrosine, histidine or tryptophan, wherein the amino acid is in the D- or L-configuration, or
wherein -LP(PEG)- has the structure of:
or a pharmaceutical acceptable salt thereof, wherein
wherein subscript v is an integer ranging from 1 to 4;
XLP is selected from the group consisting of —O—, —NRLP—, —S—, —S(═O)—, —S(═O)2—, —C(═O)—, —C(═O)N(RLP)—, —N(RLP)C(═O)N(RLP)—, —N(RLP)C(═NRLP)N(RLP)—, and C3-C8 heterocyclo, in particular —O—, —NH, —S— and —C(═O)—;
wherein each RLP is independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl, or two of RLP together along with the carbons atoms to which they are attached and their intervening atoms define a C5-C6 heterocyclo and any remaining RLP are as previously defined;
Ar is a C6-C10 arylene or a C5-C10 heteroarylene, optionally substituted;
each RE and RF is independently selected from the group consisting of —H, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkylene, optionally substituted C6-C10 arylene and optionally substituted C5-C10 heteroarylene, in particular hydrogen and C1-C4 alkyl
or RE and RF together with the carbon atom to which both are attached defines an optionally substituted spiro C3-C6 carbocyclo, or RE and RF from adjacent carbon atoms together with these atoms and any intervening carbon atoms defines an optionally substituted C5-C6 carbocyclo with any remaining RE and RF as previously defined, or
wherein the side chain of —[C(RE)(RF)]v—XLP— is provided by a natural or un-natural amino acid side chain; and
wherein the wavy lines indicate the sites of covalent attachments within the remainder of the Conjugate structure;
in particular having the PEG Unit represented by:
wherein the wavy line indicates site of attachment to XLP of the Parallel Connector Unit (LP);
subscript n′ independently ranges from 1 to 72;
RPEG1 is an optional PEG Attachment Unit;
RPEG2 is a PEG Capping Unit; and
RPEG3 is an PEG Coupling Unit,
or
having XLP—PEG with the structure of:
wherein subscript n′ is 8, 12 or 24 and RPEG2 is H or —CH3.

### Claim 52 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The Drug Linker compound of any one of claims 31-48, wherein A or a subunit thereof has the structure of formula (3) or formula (4):
wherein the wavy lines indicated covalent attachment within the composition structure;
wherein K and L′ independently are C, N, O or S, provided that when K or L′ is O or S, R41 and R42 to K or R43 and R44 to L′ are absent, and when K or L′ are N, one of R41, R42 to K or one of R42, R43 to L′ are absent, and provided that no two adjacent L′ are independently selected as N, O, or S;
wherein subscripts e and f are independently selected integers that range from 0 to 12, and subscript g is an integer ranging from 1 to 12;
wherein G is hydrogen, optionally substituted C1-C6 alkyl, —OH, —ORPR, —CO2H, CO2RPR, wherein RPR is a suitable protecting, or
G is —N(RPR)(RPR), wherein RPR are independently a protecting group or RPR together form a suitable protecting group, or
G is —N(R45)(R46), wherein one of R45, R46 is hydrogen or RPR, wherein RPR is a suitable protecting group, and the other is hydrogen or optionally substituted C1-C6 alkyl;
wherein R38 is hydrogen or optionally substituted C1-C6 alkyl;
R39-R44 are independently selected from the group consisting of hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, and optionally substituted heteroaryl,
or R30, R40 together with the carbon atom to which both are attached, or R41, R42 together with K to which both are attached when K is a carbon atom, define a C3-C6 carbocyclo, and R41-R44 are as defined herein,
or R43, R44 together with L′ to which both are attached when L′ is a carbon atom define a C3-C6 carbocyclo, and R39-R42 are as defined herein,
or R40 and R41, or R40 and R43, or R41 and R43 to together with the carbon atom or heteroatom to which both are attached and the atoms intervening between those carbon atoms and/or heteroatoms define a C5-C6 carbocyclo or a C5-C6 heterocyclo, and R39, R44 and the remainder of R40-R43 are as defined herein,
provided that when K is O or S, R41 and R42 are absent, and when K is N, one of R41, R42 is absent, and when L′ is O or S, R43 and R44 are absent, and when L′ is N, one of R43, R44 is absent, or
A or a subunit thereof is an alpha-amino, beta-amino or another amine-containing acid residue,
in particular, wherein formula (3) or formula (4) has the structure of formula (3a) or formula (4a):
wherein subscript e and f are independently 0 or 1.

### Claim 53 (depends on 31)

The Drug Linker compound of claim 31, wherein the Drug Linker compound is represent by the structure of:
or a salt thereof,
wherein
subscript a is 1 and A is an amino acid residue;
BU is a acyclic Basic Unit so that the dotted curve line is absent, and Ra2 is hydrogen, or BU together with Ra2 as C1-C6 alkyl and the carbon atom to which both are attached define a cyclic Basic Unit so that the dotted curved line is present; and
R′ is hydrogen or —NO2,
in particular by:
or a salt thereof.

### Claim 54 (depends on 1, 31)

A method of preparing a Ligand Drug Conjugate composition or compound of claim 1, the method comprising the step of: contacting a Drug Linker compound of claim 31 with a targeting agent having a reactive function group capable of interacting with the reactive functional group of the primary linker of the Drug Linker compound so as to form a covalent bond to between the Ligand Unit corresponding to the targeting agent and the primary linker of the Ligand Drug Conjugate corresponding in structure to the primary linker of the Drug Linker compound.

### Claim 55 (depends on 1, 54)

The method of claim 54, wherein the reactive functional group of the targeting agent is a cysteine thiol of an antibody, either native to the antibody through interchain disulfide bond reduction or introduced by genetic engineering into the antibody and the reactive functional group of the primary linker of the Ligand Drug Conjugate is a maleimide (M1) moiety comprising the Stretcher Unit of that primary linker, whereby said contacting of said reactive functional groups provides the Ligand Drug Conjugate composition or compound of claim 1 in which L is an antibody Ligand Unit.
